DNA markers for pancreatic ductal adenocarcinoma (PDAC) are urgently needed for detection of minimally invasive disease. The epigenetic relevance of the cysteine dioxygenase 1 gene (CDO1) has been never investigated in PDAC. Three studies, including cellular experiments, tissue validation, and pilot testing for pancreatic cytology, were carried out. Promoter DNA methylation value (MV) of CDO1 was quantified by quantitative methylation-specific PCR. CDO1 expression was consistent with its promoter DNA methylation in 7 PDAC cell lines. In 160 retrospectively collected primary PDAC tumor tissues, MV was significantly higher compared to the corresponding noncancerous pancreas (area under the receiver operating characteristic curve
| INTRODUC TI ON
Pancreatic cancer ranks 15th among malignant cancers in terms of incidence (337 872 cases in 2012) and is the seventh leading cause of cancer-related death (330 391 deaths in 2012) worldwide. 1 Pancreatic ductal adenocarcinoma (PDAC), a dominant histological type of pancreatic cancer, represents one of the most fatal malignancies, is the fourth leading cause of cancer-related deaths in the United States in 2014, and without any substantive improvement in curative therapies, is anticipated to be the second leading cause of cancer-related deaths by 2030. 2 One explanation behind its poor medical advancement is its nonspecific symptoms, resulting in delayed diagnosis and dismal prognosis. At most, only 20% of patients with PDAC present with resectable tumors. 3 Surgical resection is the only alternative for cure or long-term survival of patients with PDAC. 4 Nevertheless, the 5-year survival rate remains at approximately 10%, even after curative surgery with the best adjuvant chemotherapy. 5 To improve the prognosis of pancreatic cancer, early diagnosis is believed to be mandatory, and a simple and less invasive surveillance system has been in high demand for early diagnosis.
Pancreatic juice obtained from the endoscopic retrograde pancreatography (ERP) test is considered to be a body fluid in which PDAC cells are the most densely concentrated, and therefore, is a promising tool to diagnose PDAC. However, cytology testing using this fluid (pancreatic juice) is disappointing, because the detection rates are much lower than those for endoscopic ultrasound-fine needle aspiration (EUS-FNA) cytology or histology, which is the most popular test to confirm PDAC at present. The diagnostic accuracy of EUS-FNA histology is also estimated to be high (sensitivity and specificity of 84% and 97%, respectively). 6 However, EUS-FNA is an invasive clinical tool associated with peritoneal dissemination, and noninvasive cancer biomarkers for the early detection of PDAC have been highly anticipated.
Cancer-specific genomic or epigenetic alterations are promising for such noninvasive approaches. K-ras mutation is frequently seen in PDAC, and a meta-analysis of the diagnostic value of detecting K-ras mutation in the pancreatic juice of patients with PDAC revealed that the pooled sensitivity and specificity were 59% and 87%, respectively, which was inferior to EUS-FNA. 7 Furthermore, novel DNA methylation markers for PDAC were explored in the context of discovery, tissue validation, and pilot testing in pancreatic juice, and cluster of differentiation 1d molecule (CD1D) methylation was detected in 75% of PDAC with 95% specificity (area under the receiver operating characteristic curve [AUC] = 0.92) in pancreatic juice. 8 These findings suggested that promoter DNA methylation is more promising than K-ras mutation in pancreatic juice diagnosis.
The cysteine dioxygenase 1 gene (CDO1) is a tumor suppressor gene in human cancer that was identified by a pharmacological unmasking microarray. [9] [10] [11] CDO1 encodes a nonheme iron enzyme that converts cysteine to cysteine sulfinic acid that affects mitochondria function, while it suppresses the production of glutathione from cysteine and induces reactive oxygen species generation, subsequently promoting apoptosis. 12 CDO1 plays a role as a tumor suppressor gene. As it is a methylation-specific gene in human cancer, CDO1 methylation has been recently reported in a variety of cancers, such as esophageal, 11, 13, 14 lung, 15 gastric, 11, 16 breast, 11, 12, 17 biliary tract, 18 colorectal, 11, 19 kidney, 20 prostate, 21 bladder, 11 penile, 22 and uterine cancers. 23 However, there has been no report on the involvement of CDO1 in PDAC. To the best of our knowledge, this study represents the first investigation of the clinical relevance of methylation of the CDO1 promoter DNA in PDAC tissues and its diagnostic potential in pancreatic juice. Organization (approval no. B18-017). All patients gave written informed consent for any pathological investigation.
| MATERIAL S AND ME THODS
To diagnose PDAC, pancreatic juice cytology was carried out along with ERP or EUS-FNA. We prospectively registered 43 patients from whom pancreatic cytology samples of PDAC with no prior chemotherapy were collected (n = 37) and those suffering from pancreatic benign disease (n = 6), chronic pancreatitis (n = 4), and autoimmune pancreatitis (n = 2). Among the 37 patients with PDAC, Both studies (approval numbers B16-105 and B18-017) were carried out in accordance with the Declaration of Helsinki. DNA Methylation-Gold Kit (Zymo Research) and the bisulfited DNA was subsequently amplified by quantitative methylation-specific PCR (Q-MSP). Primer sequences were designed to recognize the DNA alterations as previously described. 19 
| Cell lines

| Quantitative methylation-specific PCR
Quantitative methylation-specific PCR was carried out using iQ Supermix (Bio-Rad) in triplicate on a C1000 Touch Thermal Cycler CFX96 Real Time System (Bio-Rad). Serial dilutions of bisulfite modified DNA from DLD1 was used to construct the calibration curve on each plate as a methylation positive control, and HepG2 served as a methylation negative control as reported. 19 The methylation value (MV) was defined by a ratio of amplified signal value of methylated CDO1 normalized to β-actin, then multiplied by 100
(Q-MSP value).
| RNA extraction and RT-PCR
Total RNA from cell lines was extracted using RNeasy Mini Kit (Qiagen), and was reverse-transcribed with a Super Script III reverse transcriptase kit (Invitrogen). Primers sequences for CDO1 and β-actin were described previously. 18 Reverse transcription-PCR was undertaken by 30 cycles of 95°C for 1 minute, 58°C for 1 minute, and 72°C for 1 minute. The PCR products were separated on 1.5% agarose gel, and then visualized by ethidium bromide staining. β-Actin was used as an internal control. 
| Immunohistochemistry
Immunostaining was carried out on FFPE sections (4 μm thick).
Sections were incubated using the anti-CDO1 rabbit polyclonal Ab (dilution of 1:100) (Atlas Antibodies). Immune complexes were detected with a Histofine Simple Stain MAX PO (MULTI) (Nichirei), following the manufacturer's protocol, and visualized using the 3,3′-diaminobenzidine substrate. Sections were counter-stained with hematoxylin solution.
| Statistical analysis
Student's t test was used for analysis of continuous variables, and the χ 2 test was used for analysis of categorical variables.
Clinicopathological characteristics and follow-up data were analyzed in terms of the disease-specific survival (DSS), which was measured from the date of operation to the date of cancer-specific death or last follow-up. The DSS was calculated by the Kaplan-Meier method, and survival differences were assessed using the log-rank test. Variables suggested to be prognostic factors in univariate analysis (P < .05) were subjected to multivariate analysis using a Cox proportional hazards model. A P value < .05 indicated statistical significance. All statistical analyses were undertaken using the SAS software package JMP Pro14 (SAS Institute).
| RE SULTS
| Methylation and expression profiles of CDO1 in PDAC cell lines
We initially examined 7 PDAC cell lines to examine the expression status of CDO1. CDO1 expression was not detected at the mRNA level in any of the PDAC cell lines, unlike HepG2 cells ( Figure 1A ). We We further investigated whether CDO1 MV could predict prognostic outcomes of PDAC. A Kaplan-Meier curve of DSS was constructed for the 160 patients according to the CDO1 MV, and P value and relative risk (RR) were plotted to analyze survival differences between CDO1 MV above and below the best optimized cut-off values, determined by using the logrank test ( Figure 3A) . We determined the best optimal cut-off value for prognostic stratification using the log-rank plot analysis. 24, 25 We thereby defined the optimal cut-off value of the CDO1 MV as 19.0, which indicated the highest RR with statistical significance (P < .05). Using this cut-off value to divide the patients into hyper-and hypomethylation groups, the CDO1 hypermethylation group showed a 5-year survival rate of 16.3%
(n = 79), whereas the CDO1 hypomethylation group showed a 5-year survival rate of 24.5% (n = 81). The prognostic difference between these 2 groups was highly significant (P = .024) ( Figure 3B ).
| Univariate and multivariate prognostic analyses including CDO1 methylation status in patients with PDAC
The characteristics of 160 patients with PDAC and the univariate prognostic factors are summarized in Table 1 . Univariate prognostic factors involved lymphatic permeation factor (P = .025), vascular permeation factor (P = .017), intrapancreatic nerve invasion factor (P = .00024), retropancreatic tissue invasion factor (P = .0062), portal venous system invasion factor (PV; P = 0.014), extrapancreatic nerve plexus invasion factor (P = .0002), arterial system invasion factor (P = 0.002), preoperative serum CA19-9 level (P < .0001), CDO1 MV (P = .024), dissected peripancreatic tissue margin factor (DPM; P < .0001), and UICC stage (P < .0001).
The clinicopathologic factors related to prognosis were then examined in the multivariate analysis. We found that PV (P = .0073, RR = 2.1), arterial system invasion factor (P = .03, RR = 3.5), preoperative serum CA19-9 level (P = .0003, RR = 2.9), and DPM positive (P = .0002, RR = 2.4) were independent of UICC stage (P = .0027) in 160 patients with PDAC. Moreover, high CDO1 MV was not an independent prognostic factor (P = 0.3). However, CDO1 methylation status was associated with UICC stage. The CDO1 MV at each UICC stage is shown in Figure 3C . Stage 0 is not described be- 
| Correlation of CDO1 methylation level to prognostic factors in patients with PDAC
The correlation of promoter DNA methylation of CDO1 to clinicopathologic factors of PDAC by the χ 2 test is shown in Table 2 . High CDO1 MV groups were significantly related to pathological factors that are involved in UICC stage determination, such as T factor and N factor. In addition, high CDO1 MV groups were related to pathological factors, such as intrapancreatic nerve invasion, retropancreatic tissue invasion factor, PV, arterial system invasion, extrapancreatic nerve plexus invasion, and DPM, which were negative prognostic factors in PDAC as revealed by univariate analysis. This might explain elimination of CDO1 hypermethylation as an independent prognostic factor in PDAC.
| Potential utility of CDO1 methylation as a tumor diagnostic marker
Methylation of CDO1 promoter DNA was significantly higher in pan- 
| D ISCUSS I ON
As K-ras mutation occurs in the precancerous lesion of PDAC, 26 epigenetic alterations might be more promising than genetic alterations for the development of simple and less invasive surveillance systems F I G U R E 2 Methylation value (MV) of CDO1 promoter DNA in 160 primary pancreatic ductal adenocarcinoma (PDAC) tissues. A, Quantitative methylationspecific PCR assessment was used to examine the MV in 160 primary PDAC tissues and 160 corresponding noncancerous pancreatic tissues (CN). B, MV of CDO1 was significantly different between primary PDAC tissue and CN (P < .0001). C, Receiver operating characteristic curve of CDO1 methylation to differentiate primary PDAC tumors from CN. The area under the curve (AUC) represents the accuracy in discriminating normal from tumor tissue in terms of sensitivity and specificity (AUC = 0.97, P < .0001). D, Representative images of immunostaining with an anti-CDO1 Ab are shown. Colon tissue is shown as a positive control. In NC, CDO1 protein was expressed in epithelium (red arrows), islet (black arrow), and acinar cells (white arrow). In the PDAC tissue, CDO1 protein was not expressed in epithelium for PDAC. 7 Moreover, recent rigorous exploration of DNA methylation markers identified extraordinarily cancer-specific and prevalent aberrations of DNA methylation in human cancer, [9] [10] [11] 27 and revealed that the length range of promoter DNA methylation was larger than In this study, for the first time, we showed that CDO1 methylation in PDAC was cancer-specific and extremely distinctive, because CDO1 methylation is hardly seen in the CN. This finding suggested CDO1 methylation occurs in PDAC cancer tissues in a very specific manner, and detection of CDO1 methylation is derived from a pinpoint tumor clone. The development of an endoscopic technique for collection of pancreatic fluid, termed endoscopic pancreatic function testing, has led to improved understanding of these alterations and is particularly helpful in characterizing pancreatic cancer.
Moreover, its frequencies in PDAC tumor tissues are so high that it presents extraordinary potential to detect cancer cells in pancreatic juice in this current study. The AUC was beyond 0.9, and sensitivity of cancer detection was at least 95% in the pancreatic juice. This is remarkable for the diagnosis of PDAC because, for the same samples, cytology testing diagnosed PDAC in only 33% of samples using conventional biopsy and in 88% of samples using EUS-FNA cytology, both of which are inferior to our current result.
In hepatopancreaticobiliary cancer, pancreaticoduodenectomy is needed for cure but it has a high mortality rate, 29 Techniques such as proteomics, cytokines, genetic mutation, DNA methylation, and microRNA analyses can be utilized to gain a better understanding of the molecular characteristics of pancreatic diseases. 30 In pancreatic cancer, recently, 4 sequential case-control studies (discovery, technical validation, biological validation, and clinical piloting) were carried out to determine the diagnostic utility of the methylation of highly relevant gene CD1D F I G U R E 3 Prognostic analysis of the methylation of CDO1 promoter DNA in 160 patients with pancreatic ductal adenocarcinoma (PDAC). A, Identification of an optimal cut-off value for the prognosis using log-rank plot analysis and relative risk (RR) plot. Note that RR became high as the methylation value of CDO1 increased. B, Kaplan-Meier curve for CDO1 methylation status with value above or below 19.0 in primary PDAC. The prognostic difference between these 2 groups showed high statistical significance (P = .024). C, Correlation of CDO1 methylation level to UICC stage. Methylation levels of CDO1 showed significant differences between Stage I and Stage II. There was no significant difference between other stages of PDAC. †P < .0001. CN, corresponding noncancerous pancreatic tissue; N.S., not significant; T, PDAC tumor tissue (encoding a member of the CD1 family of transmembrane glycoproteins) methylation. 8 Results of these studies showed that CD1D methylation in the pancreatic juice yielded an AUC value of 0.92 for patients with pancreatic cancer compared to patients with normal pancreas and chronic pancreatitis. CD1D methylation in the pancreatic juice detected pancreatic cancer with 75% sensitivity and 95% specificity. In our current study, CDO1 methylation in the pancreatic juice is likely to be superior to CD1D methylation, because its sensitivity of cancer detection is as frequent as 95% in the pancreatic juice. Endoscopic collection of pancreatic fluid is safe and relatively straightforward, permitting opportunities for longitudinal analysis of these translational markers throughout the course of disease.
| Limitations
As an early diagnostic marker, it is necessary to examine lesions that are difficult to distinguish from malignant pancreatic tumors, such as intraductal papillary mucinous neoplasm and mucinous cystic neoplasm. We should clarify them in future experiments. Similarly, as a useful diagnostic marker for providing an early therapeutic opportunity and better outcomes, it might be better if MV could be used to diagnose Stage I PDAC. Unfortunately, in this study, there was only 1 Stage I patient, but the result was promising. The next studies are expected to solve these issues.
In conclusion, although our data are still at a pilot study stage, and a large-scale validation study is needed, methylation of CDO1 promoter DNA is extremely specific for PDAC, and accumulates with PDAC tumor progression. It could therefore be a definitive diagnostic marker of PDAC in ERP solutions and could facilitate early detection of PDAC, which is one of the most dismal among human cancers. 
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